跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 558 条关于
“N332-GT5 gp151”
全部
558
临床试验
234
药物
288
机构
9
资讯
27
8个月前
IAVI Initiates Phase 1 Trial of Novel mRNA HIV Vaccine Targeting Broadly Neutralizing Antibodies
7个月前
Single-Dose HIV Vaccine Candidate Induces Neutralizing Antibodies in Nonhuman Primates
2年前
Urticaria Emerges as Concern in Phase 1 Trial of HIV mRNA Vaccines
9个月前
GT Biopharma Advances GTB-3650 to Higher Dose Level in Phase 1 Blood Cancer Trial
去年
GT Biopharma Doses First Patient in Phase 1 Trial of GTB-3650 for Hematologic Malignancies
去年
GT Biopharma Advances GTB-3650 Phase 1 Trial to Second Cohort Following Promising Immune Activation Signals
去年
Ultragenyx's GTX-102 Shows Positive Phase 1/2 Data for Angelman Syndrome, Phase 3 Enrollment to Begin by Year-End
去年
Ultragenyx's GTX-102 Shows Sustained Improvement in Angelman Syndrome Patients in Phase 1/2 Data
去年
Ultragenyx's GTX-102 Shows Promise in Angelman Syndrome Phase 1/2 Trial
去年
InnoCare Doses First Subject in Phase III Trial of TYK2 Inhibitor ICP-332 for Atopic Dermatitis
第 1 页,共 3 页
上一页
下一页